Marketing
-
Deep Dive5 insights from a chat with Larry Merlo, CEO of CVS Health
Healthcare Dive talked to Merlo about competing with Amazon, the path to buying Aetna and new areas in which CVS could play a role.
By Rebecca Pifer • Oct. 23, 2019 -
SponsoredAssessing provider (and patient) motivation
Behavioral science provides a roadmap to understanding how HCPs make decisions and what drives prescribing behavior, but more importantly, it gives us strategies that we can apply to disrupt the status quo.
By Patty Zipfel, PhD, ISMPP, CMPP™ VP, Scientific Strategy MicroMass Communications, Inc. • Oct. 23, 2019 -
Novartis' Zolgensma starts strong as about 100 infants are treated with gene therapy
Sales totaled $160 million in the gene therapy's first full quarter of commercial availability, well above Wall Street's expectations.
By Andrew Dunn • Oct. 22, 2019 -
Vertex wins speedy approval for cystic fibrosis triplet
With Trikafta cleared by the Food and Drug Administration, Vertex estimates its drugs can treat as much as 90% of patients with the lung condition.
By Jacob Bell • Oct. 21, 2019 -
Teva offers $23B of Suboxone to get out of opioid litigation
Whether such a deal would be widely accepted wasn't clear, however, amid reports attorneys for plaintiff municipalities had already rejected Teva's "agreement in principle."
By Jonathan Gardner • Oct. 21, 2019 -
Novartis backs away from marketing Pear digital therapeutics
While Sandoz and Pear are still working together, the Swiss pharma unit will no longer co-promote the recently launched reSET and reSET-O.
By Kristin Jensen • Oct. 16, 2019 -
SponsoredNative ISI rich media: A prescription for the ultimate digital pharma campaign
In a rapidly growing industry, solutions exist that meet the two key criteria of a successful pharmaceutical campaign: visibility and compliance.
-
HHS pitches sweeping revamp of Anti-Kickback Statute, Stark Law
Pharmaceutical companies are excluded from the changes, but HHS head Alex Azar said work is ongoing on separate regulations for the drug industry.
By David Lim • Oct. 09, 2019 -
Eylea casts a shadow over Novartis' latest approval
At least one analyst sees few reasons for doctors to use Novartis' Beovu in place of the Regeneron eye drug, citing a less-than-ideal label.
By Jacob Bell • Oct. 08, 2019 -
Buttigieg targets pharma in aggressive plan to lower drug prices
The presidential hopeful supports several policies, such as direct drug price negotiation, that feature in legislation proposed by House Democrats.
By Ned Pagliarulo • Oct. 07, 2019 -
Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion
The FDA approved Descovy to prevent HIV infection in adults and adolescents, but not for cisgender women.
By Jacob Bell • Oct. 04, 2019 -
SponsoredHow to relaunch your healthcare website in the new era of search
Patient search behavior has changed. Here's what to expect when relaunching your healthcare website.
-
Gene therapy stocks have taken a beating. Their recovery may be slow
Share prices of at least 26 gene therapy biotechs are down from last October, a sign that investors may want more clarity on how the drugs will be sold.
By Jacob Bell • Oct. 03, 2019 -
J&J paying $20M to settle Ohio opioid suits
The pharma giant joins Endo, Mallinckrodt and Allergan in reaching a settlement deal with Cuyahoga and Summit counties in Ohio.
By Ned Pagliarulo • Oct. 02, 2019 -
SponsoredLook beyond ROI to optimize TV campaigns
Don’t leave precious dollars on the table.
By Crossix Solutions • Sept. 30, 2019 -
AstraZeneca, Merck strengthen lead in PARP drug class
AbbVie appears back on track with rival veliparib, but until it's approved Lynparza looks set to be a preferred option in first-line ovarian cancer.
By Jonathan Gardner • Sept. 28, 2019 -
Top Pelosi aide to payers: Help us defeat Big Pharma
Wendell Primus' pitch sparked debate between policy experts and industry representatives Monday at AHIP's annual conference.
By Samantha Liss • Sept. 24, 2019 -
Public health alert or legal advertising? It can be hard to tell.
"It's whack-a-mole; it really is," Aviva Wein, J&J's assistant general counsel for product liability, said of the increasing number of ads targeting devices.
By Dana Elfin • Sept. 24, 2019 -
Q&ADoes disclosure of pharma payments harm patient trust in doctors?
A counterintuitive finding raises questions about how transparency can be better managed, University of Pennsylvania researcher Genevieve Kanter told BioPharma Dive.
By Andrew Dunn • Sept. 23, 2019 -
States pull back curtain on drug prices, to uncertain effect
A newly enacted law in Colorado requires pharma companies inform doctors of list prices, as well as the names of three generics in the same treatment class.
By Ned Pagliarulo • Sept. 23, 2019 -
Deep DiveIs the future of diabetes treatment better drugs or better care?
Drug manufacturers are trying to push the boundaries of glucose control, but cost concerns could rein in ambitions.
By Jonathan Gardner • Sept. 23, 2019 -
Regulatory barriers limit alternative state drug payment models
Forced to balance higher costs with public health goals, more states are looking at alternative payment models for prescription drugs in Medicaid.
By Samantha Liss • Sept. 18, 2019 -
J&J finds competitive edge with latest Erleada approval
The advantage may be short-lived, however, as a rival prostate cancer drug from Pfizer could notch a similar approval in the fourth quarter.
By Jacob Bell • Sept. 18, 2019 -
Vertex makes headway in UK reimbursement
Scotland has agreed to cover two Vertex drugs, Orkambi and Symkevi, which may bode well for resolving a dispute over the company's prices.
By Jacob Bell • Sept. 12, 2019 -
Survey suggests Ionis is losing battle against Pfizer and Alnylam
Physician preferences between the company's respective drugs appear to be emerging in the year since Ionis' Tegsedi won approval.
By Jacob Bell • Sept. 10, 2019
